Tender Offer to Make Nissui Pharmaceutical a Wholly Owned Subsidiary
First written in FY2022. 2 of 6 entries say "Advanced", first in FY2023-Q1. Latest entry: FY2024-Q3.
No other company in this theme has enough history to compare yet.
- FY2024-Q3Cited as achievedAnnual report
「Although sales of COVID-19-related products declined, the results of Shimadzu Diagnostics, which became a consolidated subsidiary in September 2022, contributed.」
The results of 島津ダイアグノスティクス following its consolidation as a subsidiary after 日水製薬 was made a wholly owned subsidiary continued to contribute to revenue growth in the Measuring Instruments business. - FY2024-Q1Cited as achievedAnnual report
「The results of Shimadzu Diagnostics Corporation also contributed.」
Regarding the business following the acquisition of Nissui Pharmaceutical as a wholly owned subsidiary, the company reported that the results of Shimadzu Diagnostics Corporation contributed to the measuring instruments business in the first quarter under review. - FY2023-Q3AchievedAnnual report
「As the company did not own all of the target company's shares, excluding treasury shares held by the target company, after completion of settlement for the tender offer for the company's own shares, the target company carried out a share consolidation, effective 15 November 2022, as a squeeze-out procedure to make the target company a wholly owned subsidiary of the company. The company obtained court approval to additionally acquire the fractions of less than one share arising from the share consolidation pursuant to Article 234, Paragraph 2 of the Companies Act as applied mutatis mutandis under Article 235, Paragraph 2 of the same Act (Act No. 86 of 2005, as subsequently amended), and the target company became a wholly owned subsidiary of the company.」
Following the tender offer for Nissui Pharmaceutical, the consolidation of shares and additional acquisition of fractional shares were completed, achieving full ownership as a subsidiary on 15 November 2022. - FY2023-Q2AdvancedAnnual report
「As a result of the share repurchase tender offer, the target company became a consolidated subsidiary of the company as of 29 September 2022, the commencement date of settlement for the share repurchase tender offer.」
As part of the procedures to make Nissui Pharmaceutical a wholly owned subsidiary, it became a consolidated subsidiary on 29 September 2022 upon settlement of the tender offer for its own shares, bringing the post-acquisition voting rights ratio to 78.91%. A share consolidation for the remaining shareholders is scheduled to take effect on 15 November 2022. - FY2023-Q1AdvancedAnnual report
「The tender offer commenced on 17 June 2022 and ended on 28 July 2022.」
The tender offer to make Nissui Pharmaceutical a wholly owned subsidiary was successful, with 7,766,262 shares acquired and the ownership ratio after the tender offer reaching 34.68%. A squeeze-out is planned through a self-tender offer by the target company, followed by a share consolidation or a demand for the sale of shares, and the process of making the company a wholly owned subsidiary has not yet been completed. - FY2022First statedAnnual report
「At a meeting of the Board of Directors held on 31 May 2022, the Company resolved to acquire common shares of Nissui Pharmaceutical Co., Ltd. through a tender offer with the aim of making Nissui Pharmaceutical Co., Ltd. a wholly owned subsidiary, and entered into a basic agreement with Nippon Suisan Kaisha, Ltd. and Nissui Pharmaceutical Co., Ltd.」
A tender offer to make Nissui Pharmaceutical a wholly owned subsidiary was approved and launched on 17 June 2022. The offer price was ¥1,714 per share and the planned acquisition was 10,288,054 shares, with synergies expected from antibody manufacturing capacity and cell-culture technologies.